Antibody Drug Conjugate - Competitive Landscape 2023 Study: Featuring Coverage on 180+ Companies and 300+ Drugs

News provided by

Jun 30, 2023, 14:00 ET

DUBLIN, June 30, 2023 /PRNewswire/ -- The "Antibody Drug Conjugate- Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering.

This "Antibody Drug Conjugate- Competitive landscape, 2023" report provides comprehensive insights about 180+ companies and 300+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Antibody Drug Conjugate: Overview

Antibody-drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components. Selection of an appropriate target, an mAb, cytotoxic payload, and the manner in which the antibody is linked to the payload are key determinants of the safety and efficacy of ADCs. Antibody-drug conjugate (ADC) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. The concept of ADC was first presented by the German physician and scientist Paul Ehrlich almost 100 years before. One of the most important aspects of ADC development for cancer is the identification of the unique antigenic target of the mAb component. There are 328 unique antigens used in antibody-based therapy as a target.

The selected antigen needs to fulfill several requirements. First, the target antigen needs to have high expression in the tumor and no or low expression in the healthy cell. Second, the target antigen should be displayed on the surface of the tumor cell to be available to the circulated mAb. Third, the target antigen should possess internalization properties as it will facilitate the ADC to transport into the cell, which will in turn enhance the efficacy of the cytotoxic agent. In ADCs, the most targeted antigens are ERBB2, CD19, CD33, CD22, and MSLN (mesothelin). In addition, over 50 different known antigens have been used in ADC as a target. However, previous studies showed that some tumor antigens also show low expression in the normal cell. The idea behind ADCs is the optimal delivery of a highly potent payload to its target using a specific carrier. Administration of ADCs is done intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Ideally, exclusive expression of the target antigens on tumor cells, but not on normal cells, is the prerequisite for the mAb component of ADCs to find and bind to it. Upon recognition and attaching to its target, internalization of the ADC-antigen complex into the cell takes place via receptor-mediated endocytosis. Internalization takes place via three different routes: (i) clathrin-mediated endocytosis (the major route of intracellular uptake of ADCs), (ii) caveolae-mediated endocytosis, and (iii) pinocytosis. The rate and efficiency of the ADC-antigen complex to be internalized depends on the type of target and the cytotoxic compounds. Insufficient affinity (Kd > 10 nmol/L), in case of low binding affinity that does not result in binding to the receptor, may result in inefficient internalization leading to the off-target release of ADC and therefore results in systemic toxicity.

Report Highlights

In April 2023, Mythic Therapeutics, announced preclinical data highlighting the potential of MYTX-011, its investigational cMET-targeting ADC, for treating a broader range of cMET+ cancers than other cMET-targeting ADCs in development. These data were presented as a poster at the American Association for Cancer Research Annual Meeting. MYTX-011 demonstrated higher internalization in cMET+ tumor cells and broader, more potent efficacy, including a greater than 3-fold increase in efficacy in mouse models of NSCLC, as compared to other cMET-targeting ADCs.
In April 2023, Araris Biotech AG, announced the company delivered two poster presentations at this year's American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida. The presentations highlighted late-breaking preclinical data on anti-Nectin-4 and anti-HER2 ADCs generated using the company's proprietary linker technology. Both ADCs demonstrated improved anti-tumor activity compared to respective FDA approved ADCs in head-to-head in-vivo studies.

Antibody Drug Conjugate: Analytical Perspective

In-depth Commercial Assessment: Antibody Drug Conjugate: Collaboration Analysis by Companies

The Report provides an in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate: Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Antibody Drug Conjugate Report Assessment

Company Analysis
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions Answered

How many companies are developing Antibody Drug Conjugate drugs?
How many Antibody Drug Conjugate drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Antibody Drug Conjugate?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Antibody Drug Conjugate therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Antibody Drug Conjugate and their status?
What are the key designations that have been granted to emerging and approved drugs?

Key Players

NBE-Therapeutics
ImmunoGen, Inc.
Seagen Inc.
ADC Therapeutics
Mythic Therapeutics
Sutro Biopharma
Merck KGaA
Sorrento Therapeutics, Inc.
Peak Bio
Regeneron Pharmaceuticals
Asana BioSciences
Tanabe Research Laboratories USA
OBI Pharma
Sanofi
Navrogen, Inc.

Key Products

Zynlonta
Ladiratuzumab Vedotin
NBE-002
IMGN151
Camidanlumab tesirine
ADCT-602
ADCT-901
ADCT-701
ADCT-212
ADCT-601
IMGN-632
IMGC 936
IMGN-151
MYTX-011
M1231
STI-6129
Torpedo
BCMA ADC
REGN5093-M114
ASN004
TR 1801 ADC
OBI 999
R 992
NAV-001

For more information about this report visit https://www.researchandmarkets.com/r/gsegj8

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets